Allergic rhinitis
Conditions
Interventions
Intervention group:Vitamin D3 drops (Yueer) 1600 IU po qd *90 days, using nasal spray glucocorticoid mometasone furoate (Nesuna) and antihistamine loratadine tablets (Beixue) were used to control symp
Control group:Mometasone furoate (Nesuna) and desloratadine citrate tablets (Beixue) , an antihistamine, were used to control symptoms and use nasal decongestants for a short time if necessary.
Sponsors
First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
12 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Aged 12-40 years old, male or female; 2. According to "Guidelines for Diagnosis and Treatment of Allergic Rhinitis in China (2022, Revised Edition)", Diagnosed as allergic rhinitis, with typical clinical symptoms and serum specific IgE nodules results clearly contain at least one item of house dust mite/dermatophagoides farinae; 3. Have not received immunization and biological monoclonal antibody treatment; 4. The basic demographic information is complete and can be followed up regularly; 5. Agree to abide by the relevant provisions of clinical trials and sign an informed consent form; 6. Patients with allergic rhinitis whose serum 25(OH)D level is less than 50 nmol/L enter the interventional research.
Exclusion criteria
Exclusion criteria: 1.At the same time, it is difficult to control other upper and lower respiratory diseases, and it is necessary to inhale or take glucocorticoids hormone drugs orally for a long time, such as chronic rhinitis, sinusitis, bronchial asthma, etc. 2. Past diseases related to gastrointestinal tract, liver and gallbladder, chronic diarrhea caused by various reasons and indigestion.Patients with a history of biliary and hepatobiliary surgery; 3.diseases such as autoimmune and endocrine diseases that may affect vitamin D metabolism, such as systemic Lupus erythematosus, rheumatoid arthritis, hyperthyroidism or hypothyroidism caused by various reasons, Need long-term drug control; 4.n the past month, have taken anticonvulsants such as phenobarbital and phenytoin sodium, and tricyclic antidepressants drugs, aluminum-containing gastric mucosal protective agents such as aluminum hydroxide, rifampicin and other antibiotics and other drugs that affect the metabolism and absorption of vitamin D and any vitamin D supplements; 5.Allergen-specific immunotherapy (desensitization therapy) was started within 3 months before entering the study, and any patient who has received biological monoclonal antibody treatment or plans to undergo related treatment; 6.Pregnant or planned pregnant or lactating patients; 7.Those who have a history of psychotropic drug abuse and can't quit or have mental disorders; 8.Patients with severe obesity (BMI > 30); 9. Patients who have participated in other clinical trials at the same time; 10.Other researchers think it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analogue scale;Rhinoconjunctivitis Quality of Life Questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine blood test;Serum 25-hydroxyvitamin d;Serum total IgE;Serum specific IgE;Interleukin-4;Interferon ?;Histamine;Mast cell protease;Interleukin10;Eosinophil cationic protein;cytochrome P450 family 27 subfamily B member 1;Cytochrome P450 Family 24 Subfamily A Member 1;Eosinophil count;Eosinophil%; | — |
Countries
China
Contacts
Public ContactYe Jing
First Affiliated Hospital of Nanchang University
Outcome results
None listed